Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2022-05-10 Interim / Quarterly Rep…
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2022
2022-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2022, reporting the company's financial results for the first quarter ended March 31, 2022. It includes a press release announcing financial results as Exhibit 99.1. The text explicitly states that the information is furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document is short (4007 characters) and primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2022-05-10 English
Regulatory Filings 2022
Regulatory Filings
2022-05-10 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Reneo Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a correspondence related to a securities registration process, specifically a request for the SEC to declare the registration statement effective earlier than originally planned. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising but not a direct announcement of financing or capital structure changes. Given the nature of the document as a formal regulatory correspondence requesting acceleration of a registration statement's effective date, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. The document length is short and it is not a report or presentation itself, so it is not a Capital/Financing Update (CAP) or Report Publication Announcement (RPA).
2022-05-05 English
Regulatory Filings 2022
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or other specific report type.
2022-05-04 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes a base prospectus and a sales agreement prospectus for offerings of common stock, preferred stock, debt securities, and warrants. The document is a detailed registration statement and prospectus, not an announcement or a brief summary. It is not an earnings release, annual report, or any other financial report type. It is clearly related to capital raising activities and securities offerings. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full registration statement, not a short announcement or certification.
2022-05-02 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.